![]() |
Name |
notoamide D
|
Molecular Formula | C26H31N3O4 | |
IUPAC Name* |
(1R,13S,16S,22S)-1-hydroxy-7,7-dimethyl-13-(2-methylbut-3-en-2-yl)-6-oxa-12,14,20-triazahexacyclo[11.10.0.02,11.05,10.014,22.016,20]tricosa-2(11),3,5(10),8-tetraene-15,21-dione
|
|
SMILES |
CC1(C=CC2=C(O1)C=CC3=C2N[C@@]4([C@]3(C[C@@H]5N4C(=O)[C@@H]6CCCN6C5=O)O)C(C)(C)C=C)C
|
|
InChI |
InChI=1S/C26H31N3O4/c1-6-23(2,3)26-25(32,14-18-21(30)28-13-7-8-17(28)22(31)29(18)26)16-9-10-19-15(20(16)27-26)11-12-24(4,5)33-19/h6,9-12,17-18,27,32H,1,7-8,13-14H2,2-5H3/t17-,18-,25+,26-/m0/s1
|
|
InChIKey |
ZPTMKNVJQZMLNE-SSQYTKQRSA-N
|
|
Synonyms |
notoamide D; Notamide D; (-)-notoamide D; CHEMBL4105208; CHEBI:145686; NSC789225; NSC-789225; (1R,13S,16S,22S)-1-hydroxy-7,7-dimethyl-13-(2-methylbut-3-en-2-yl)-6-oxa-12,14,20-triazahexacyclo[11.10.0.02,11.05,10.014,22.016,20]tricosa-2(11),3,5(10),8-tetraene-15,21-dione; (6bR,7aS,12aS,14aS)-6b-hydroxy-3,3-dimethyl-14a-(2-methylbut-3-en-2-yl)-3,6b,7,7a,10,11,12,12a,14a,15-decahydro-8H,13H-pyrano[2,3-g]pyrrolo[1'',2'':4',5']pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-8,13-dione; 937251-98-4
|
|
CAS | NA | |
PubChem CID | 16127841 | |
ChEMBL ID | CHEMBL4105208 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 449.5 | ALogp: | 3.1 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 82.1 | Aromatic Rings: | 6 |
Heavy Atoms: | 33 | QED Weighted: | 0.672 |
Caco-2 Permeability: | -4.891 | MDCK Permeability: | 0.00002450 |
Pgp-inhibitor: | 0.997 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.131 | 20% Bioavailability (F20%): | 0.186 |
30% Bioavailability (F30%): | 0.844 |
Blood-Brain-Barrier Penetration (BBB): | 0.183 | Plasma Protein Binding (PPB): | 92.55% |
Volume Distribution (VD): | 1.275 | Fu: | 5.22% |
CYP1A2-inhibitor: | 0.014 | CYP1A2-substrate: | 0.126 |
CYP2C19-inhibitor: | 0.76 | CYP2C19-substrate: | 0.846 |
CYP2C9-inhibitor: | 0.931 | CYP2C9-substrate: | 0.74 |
CYP2D6-inhibitor: | 0.194 | CYP2D6-substrate: | 0.16 |
CYP3A4-inhibitor: | 0.97 | CYP3A4-substrate: | 0.952 |
Clearance (CL): | 3.601 | Half-life (T1/2): | 0.066 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.832 |
Drug-inuced Liver Injury (DILI): | 0.96 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.891 | Maximum Recommended Daily Dose: | 0.944 |
Skin Sensitization: | 0.182 | Carcinogencity: | 0.964 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.691 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004064 | ![]() |
0.632 | D02IQY | ![]() |
0.273 | ||
ENC002535 | ![]() |
0.583 | D06YFA | ![]() |
0.257 | ||
ENC003156 | ![]() |
0.508 | D01TSI | ![]() |
0.244 | ||
ENC004604 | ![]() |
0.500 | D0V3ZA | ![]() |
0.237 | ||
ENC004947 | ![]() |
0.492 | D0SP3D | ![]() |
0.231 | ||
ENC004065 | ![]() |
0.492 | D09NNH | ![]() |
0.230 | ||
ENC002052 | ![]() |
0.423 | D0W7RJ | ![]() |
0.224 | ||
ENC001985 | ![]() |
0.417 | D0P0HT | ![]() |
0.216 | ||
ENC005468 | ![]() |
0.408 | D0V4WD | ![]() |
0.216 | ||
ENC002536 | ![]() |
0.408 | D0D2VS | ![]() |
0.216 |